Le Lézard
Classified in: Health, Covid-19 virus
Subjects: CHI, SVY, DEI

Half of Kids with Inflammatory Syndrome After COVID-19 Have Neurologic Symptoms


MINNEAPOLIS, April 17, 2021 /PRNewswire/ -- Half of the children who developed the serious condition associated with COVID-19 called multisystem inflammatory syndrome in children (MIS-C) had neurologic symptoms or signs when they entered the hospital, according to preliminary research that will be presented at the American Academy of Neurology's 73rd Annual Meeting being held virtually April 17 to 22, 2021. Those symptoms included headaches, encephalopathy and hallucinations.

"With this new inflammatory syndrome that develops after children are infected with the coronavirus, we are still learning how the syndrome affects children and what we need to watch out for," said study author Omar Abdel-Mannan, MD, of University College London in the United Kingdom and a member of the American Academy of Neurology. "We found that many children experienced neurologic symptoms involving both the central and peripheral nervous systems."

For the study, researchers reviewed the records of all children under age 18 admitted to Great Ormond Street Hospital in London between April 4, 2020, and September 1, 2020, who met the criteria for multisystem inflammatory syndrome in children.

There were 46 children with an average age of 10. Of those, 24 children had neurologic symptoms or signs that they had not experienced previously. Twenty-four had headaches, 14 had encephalopathy, six had voice abnormalities or hoarseness, six had hallucinations and five had ataxia, or impaired coordination. In addition, three children had problems with their peripheral nerves and one child had seizures.

The children with neurologic symptoms were more likely to need a ventilator and drugs to help stabilize their blood circulation than the children without neurologic symptoms. However, there were no differences in terms of demographics, inflammatory markers, management or short-term outcomes between the two groups.

"Children who develop this condition should definitely be evaluated for neurologic symptoms and longer- term cognitive outcomes," said Abdel-Mannan. "More studies are needed involving more children and following children to see how this condition changes over time and if there are any longer-term neurocognitive effects."

Learn more about COVID-19 at BrainandLife.org, home of the American Academy of Neurology's free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life® on Facebook, Twitter and Instagram.

When posting to social media channels about this research, we encourage you to use the American Academy of Neurology's Annual Meeting hashtag #AANAM.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with over 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

SOURCE American Academy of Neurology


These press releases may also interest you

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...

24 avr 2024
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024. Highlights for the Quarter: Net income available to common...

24 avr 2024
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related...

24 avr 2024
Teradyne, Inc. reported revenue of $600 million for the first quarter of 2024 of which $412 million was in Semiconductor...

24 avr 2024
Alamos Gold Inc. ("Alamos" or the "Company") today reported its financial results for the quarter ended March 31, 2024. "We delivered another strong start to the year across a number of fronts, following a record performance in 2023. Costs...



News published on and distributed by: